Andrew Kleinberg has over 8 years of experience as a synthetic organic chemist developing kinase inhibitors for cancer treatment. He has successfully designed and synthesized numerous small molecule inhibitors as part of research teams at OSI Pharmaceuticals, resulting in 5 patents and publications. Kleinberg is highly skilled in organic synthesis techniques and managing projects from hit identification to development candidates. He also has strong communication and leadership abilities.

1. Curriculum Vitae
Andrew Kleinberg
510 Lakeville Lane
East Meadow, NY 11554
Phone: (516) 965-2174 Email: andrewkleinberg@gmail.com
PROFESSIONAL PROFILE
• Results-oriented synthetic organic chemist with 8 years of research experience in biotech,
developing kinase inhibitors as anti-cancer agents
• Skilled at designing and synthesizing small-molecule inhibitors, tracking SAR and conceiving of
ways to improve the chemical matter
• Consistently received top productivity scores in the chemistry department
• Understands the importance of the balance between potency and physical properties in designing
drug-like compounds, including more cutting-edge statistics like Lipophilic Ligand Efficiency
• Great success working on all scales of reactions, with specialty in small-scale reactions for
generating final compounds with high efficiency
• Very experienced with literature-searching software (SciFinder) for quick optimization of
proprietary reactions
• Highly skilled in use of analytical equipment like LC/MS and NMR
• Proficient with many forms of compound purification, including silica gel chromatography,
triturations, reverse-phase HPLC, SFC and Solid-Phase Extraction cartridges
• Excellent communication skills, both with supervisors and in group presentations
• Acquired managerial experience while training and supervising a chemistry intern for more than a
year
• 5 times received company “SPOT” award, for recognition of above-and-beyond effort in the
chemistry department
• Friendly, team-oriented employee, always willing to spare time to help others
PROFESSIONAL EXPERIENCE
OSI Pharmaceuticals 5/2005 – 5/2013
Associate Scientist 1/2010 – 5/2013
Team member on the TAK1 inhibitor program
• Managed a chemistry intern for 14 months in support of synthetic efforts for project team
• Pioneered chemistry around key benzothiadiazole pharmacophore, leading to advanced potency,
PK and selectivity for series
• Performed majority of in vivo scale-ups for lead compounds, consistently ahead of timelines
• Led synthetic efforts from initial hits to development candidates on furopyridine series
• Designed and pioneered a novel synthetic approach to a key core intermediate by utilizing a
cycloisomerization strategy
• Helped team drive new series from early stages to compounds rivaling previous advanced series
within a few months, using lessons of physical properties and personally designing key
pharmacophores
Senior Research Associate 6/2007 –
12/2009

2. Team member on the MET/RON dual-inhibitor program
• Spear-headed synthetic efforts to two development candidates on furopyridine and azaindole
series
• Performed 100 g rat tox scale-up of development candidate to 99% purity
• Joined High-Speed Analog group, synthesizing 500+ final compounds in small quantities per
person per year
• Credited with design of first development candidate for MET/RON program after major analog
campaign which I personally conceived and performed, including scale-up of lead compound
• Developed 3-step, 1-pot method for another major analog campaign towards potency optimization
(Mitsunobu  nitro-reduction  de-BOC  HPLC purification of final compound, 3 hours
time)
• Screened chiral-auxiliaries on key racemate core intermediate for separation of diasteriomers to
identify and profile the desired enantiomer of final compounds, before chiral SFC was available
• Pioneered metallation chemistry to synthesize key selectivity pharmacophore, used in
development candidate
• Performed majority of in vivo scale-ups for lead compounds and PK-screenings, consistently
ahead of timelines
Team member on the ACK1 inhibitor program
• Explored and developed a microwave assisted, Cu(I)-mediated coupling reaction to enable a
major analog campaign of diaryl-ether pharmacophore, when conventional heating was not
working
• Generated high quality lead compounds with excellent potency, selectivity and bioavailability in a
period of 5 months, using systematic SAR exploration around the lipophilic binding site
Research Associate 8/2005 –
6/2007
Team member on the IGF-1R BU inhibitor program
• Synthesized analogs around key quinoline pharmacophore, leading to serendipitous discovery of
slow off-rate inhibitors
• Performed analog campaign of amides and various bioisosteres, leading to identification of
potential development candidate back-up, which was scaled up for in vivo profiling in tumors
• Began tenure at OSI as a summer intern, and then hired full-time
EDUCATION
M.S., Chemistry, St. John’s University, 2011
Advisor: Professor Victor Cesare
B.S., Chemistry, Penn State University, University Park, 2004
PUBLICATIONS
1. Jin, M.; Wang, J.; Kleinberg, A.; Kadalbajoo, M.; et al. Discovery of potent, selective and orally
bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors. Bioorg. Med.Chem.
Lett. 2013, 23, 979-984
2. Jin, M.; Kleinberg, A.; Cooke, A.; Gokhale, P.; Foreman, K.; Dong, H.; Siu, K.; Bittner, M.;
Mulvihill, K.; Yao, Y.; et al. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like
growth factor 1 receptor inhibitors with in vivo efficacy. Bioorg. Med.Chem.

3. Lett. 2011, 21(4), 1176-1180
3. Jin, M.; Gokhale, P.; Cooke, A.; Foreman, K.; Buck, E.; May, E.; Feng, L.; Bittner, M.; Kadalbajoo,
M.; Landfair, D.; Kleinberg, A.; et al. Discovery of an Orally Efficacious Imidazo[5,1-f]
[1,2,4]triazine Dual Inhibitor of IGF-1R and IR. ACS Med. Chem.
Lett. 2010, 1(9), 510-515
4. Li, A.; Beard, D.; Coate, H.; Honda, A.; Kadalbajoo, M.; Kleinberg, A.; Laufer, R.; Mulvihill, K.;
Nigro, A.; Rastogi, P.; et al. One-pot Friedlander quinoline synthesis: scope and
limitations. Synthesis 2010, (10), 1678-1686
PATENTS
1. Hornberger, K.; Berger, D.; Chen, X.; Crew, A.; Dong, H.; Kleinberg, A.; Li, A.; Ma, L.; Mulvihill,
M.; Panicker, B.; Siu, K.; Steinig, A.; Tarrant, J.; Wang, J.; Weng, Q.; Sangem, R.; Gupta, R.; : 7-
Aminofuropyridine derivatives. Feb. 23 2012:US20120046267
2. Muvilhill, M.; Steinig, A.; Crew, A.; Jin, M.; Kleinberg, A.; Li, A.; Wang, J. : Fused Bicyclic Kinase
Inhibitors. OSI Pharmaceuticals. Nov, 17 2011: US20110281888
3. Li, A.; Steinig, A.; Kleinberg, A.; Weng, Q.; Muvilhill, M.; Wang, J.; Chen, X.; Wang, T.; Dong, H.;
Jin, M. : Furo[3,2-c]pyridines. OSI Pharmaceuticals. Sep. 20 2011: US8022206
4. Chen, X.; Jin, M.; Kleinberg, A.; Li, A.; Muvilhill, M.; Steinig, A.; Wang, J. : Substituted
Pyrrolo[2,3-b]-Pyridines and -Pyrazines. OSI Pharmaceuticals. Sep. 15 2011: US20110224191
5. Crew, A.; Jin, M.; Kadalbajoo, M.; Kleinberg, A.; Muvilhill, M.; Wang, J. : Substituted Imidazopyr-
and Imidazotri-azines. OSI Pharmaceuticals. Nov. 19 2009: US20090286768
6. Li, A.; Steinig, A.; Kleinberg, A.; Qinghua Weng, Muvilhill, M.; Wang, J.; Chen, X.; Wang, T.;
Dong, H.; Jin, M. : Furo- And Thieno [3,2-c] Pyridines. OSI Pharmaceuticals. Aug. 6
2009: US20090197864
HOBBIES AND INTERESTS
• Managed company softball team
• Huge Mets fan
• Active in company charity events (Camp Adventure, Lustgarten Cancer Walk, charity sports
competitions, beard-growing fundraisers)
• Bowling league
References Available Upon Request